Anticoagulant drugs increase natural killer cell activity in lung cancer - Bobek, V.; Boubelik, M.; Fišerová, A.; L’uptovcová, M.; Vannucci, L.; Kacprzak, G.; Kolodzej, J.; Majewski, A.M.; Hoffman, R.M. (Lung cancer (Amsterdam, Netherlands), 2005)
Keywords: Aged; Animals; Anticoagulants; Anticoagulants - pharmacology; Anticoagulants - therapeutic use; Biological and medical sciences; Cancer; Carcinoma, Lewis Lung - immunology; Carcinoma, Non-Small-Cell Lung - immunology; Case-Control Studies; Female; Heparin; Humans; Killer Cells, Natural - immunology; Lewis lung cancer; LMWHs; Lung Neoplasms - immunology; Male; Medical sciences; Mice; Middle Aged; Natural killer cell; NK activity; Pneumology; Tumor Cells, Cultured; Tumors of the respiratory system and mediastinum; Warfarin; Natural killer cell; Anticoagulants; LMWHs; Warfarin; Lewis lung cancer; Heparin; NK activity; Cancer; Drug; Lung disease; Respiratory disease; Lung cancer; Activity; Anticoagulant; Increase; Malignant tumor; Natural; Natural iller cell; Blood group; Bronchus disease